Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to a newly hired non-executive employee under its 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The grants, effective November 3, 2025, include a non-statutory stock option for 1,100 shares at an exercise price of $11.47 (the closing price on the grant date) with a 10-year term and four-year vesting (25% vesting on October 20, 2026, then monthly over three years), and a restricted stock unit award for 367 shares vesting in equal annual installments over three years beginning November 3, 2026. Awards are subject to the award agreements and plan terms.

BEDFORD, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired non-executive employee. The award was made as an inducement material to the individual’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of November 3, 2025, and consist of a non-statutory stock option to purchase up to 1,100 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 367 shares of Ocular’s common stock. The stock option has an exercise price of $11.47 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on October 20, 2026, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit award is scheduled to vest over three years, in equal annual installments, with the first annual installment vesting on November 3, 2026, and subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with a Phase 3 clinical program for non-proliferative diabetic retinopathy (NPDR) planned to be initiated imminently.

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Explore the Company’s new corporate branding and follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

What inducement awards did Ocular Therapeutix (OCUL) grant on November 3, 2025?

Ocular granted a non-statutory option for 1,100 shares and a RSU award for 367 shares, effective November 3, 2025.

What is the exercise price and term of the OCUL stock option granted November 3, 2025?

The option has an exercise price of $11.47 (closing price on grant date) and a 10-year term.

When do the OCUL option and RSU awards vest for the November 3, 2025 grant?

The option vests 25% on Oct 20, 2026 then monthly over three years; the RSUs vest in equal annual installments with first vesting on Nov 3, 2026.

Why did Ocular Therapeutix (OCUL) issue these inducement awards under Nasdaq Rule 5635(c)(4)?

The awards were granted as inducement material to the individual’s acceptance of employment under Nasdaq Listing Rule 5635(c)(4).

Do the OCUL inducement awards affect existing shareholder approval requirements?

The awards were granted under Ocular’s 2019 Inducement Stock Incentive Plan, following the Nasdaq rule that permits inducement grants without prior shareholder approval.

Where can investors find the terms governing the OCUL November 2025 inducement grants?

The grants are subject to the specific award agreements and Ocular’s 2019 Inducement Stock Incentive Plan, which outline terms and conditions.